
The U.S. is facing sustained calls to end its opposition of a proposal to temporarily lift intellectual property rules for Covid-19 vaccines and related technology as soaring coronavirus cases ravage India and new reporting spotlights a debate within the Biden administration over whether to support the patent suspension effort to help tackle the global pandemic or prioritize Big Pharma’s interests.





